| Literature DB >> 33992108 |
Lin Li1, Donghai Zhou2, Qiuping Liu1, Dianming Li1, Qiao Wang1, Xiaowei Shi1, Chengping Wen3, Lin Huang4.
Abstract
BACKGROUND: Rheumatoid arthritis (RA), is an autoimmune inflammatory disease with increasing global morbidity and high disability. Early treatment is an effective intervention to slow down joint deformation. However, as for early RA and pre-RA patients, it sometimes takes a long time to make a definite diagnosis and few guidelines have made suggestion for these suspected or early phrase individuals. Yunpi-Qufeng-Chushi-Prescription (YQCP) is an optimization of the traditional formula, Cangzhu Fangfeng Tang which is effective for arthromyodynia management.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33992108 PMCID: PMC8122573 DOI: 10.1186/s12906-021-03311-4
Source DB: PubMed Journal: BMC Complement Med Ther ISSN: 2662-7671
Full scientific species names of herbs of Yunpi-Qufeng-Chushi-Prescription
| Pin Yin | Latin Name |
|---|---|
| Cang Zhu | Atractylodes lancea |
| fang feng | Saposhnikovia divaricata |
| qing feng teng | Sinomenium acutum |
| jin yin hua | |
| hu zhang | |
| yi yi ren | |
| Xu Chang Qing | Cynanchum paniculatum |
| Zhi Gan Cao | Radix Glycyrrhizae Preparata |
| Tu Fu Ling | Smilax glabra |
| Kun Ming Shan Hai Tang | Tripterygium hypoglaucum |
| Tu Si zi | Semen Cuseutae |
Fig. 1The molecular structure of main components. a chlorogenic acid, b polydatin, c sinomenine, e prim-o-glucosylcimifugin, f liquiritin
Fig. 2The relationships between the herbs sharing the same compounds
Fig. 3The gene ontology analysis of the YQCP predicted targets
Fig. 4The KEGG enrichment analysis of the YQCP predicted targets
Fig. 5PPIs network of YQCP and DEGs. The blue nodes stand for formula targets; the yellow nodes stand for the formula targets overlapped with DEGs; the purple nodes stand for down-expressed DEGs; the pink nodes stand for up-expressed DEGs. a; The whole PPIs network. b: sub-cluster with source > 3
The binding energy between targets and moleculars
| Target | Chlorogenic acid (kcal·mol−1) | Polydatin (kcal·mol− 1) | Prim-O-glucosylcim-ifugin (kcal·mol− 1) | Sinomenine (kcal·mol− 1) | Liquiritin (kcal·mol− 1) | Hydroxychloro-quine (kcal·mol− 1) |
|---|---|---|---|---|---|---|
| C2 | −3.75 | −4.90 | − 4.13 | −5.28 | −6.26 | −3.45 |
| C3 | −7.30 | −9.41 | −8.18 | − 9.42 | −9.49 | − 4.28 |
| IGF1R | −5.19 | −6.48 | −4.38 | −6.05 | −5.27 | −3.13 |
| MMP9 | −4.09 | −4.96 | −5.39 | −6.21 | − 4.47 | / |
| SRC | −5.05 | −5.09 | −4.40 | −6.76 | − 5.50 | −3.84 |
| KIT | −6.18 | −7.35 | − 7.36 | − 6.80 | −7.87 | − 6.33 |
| EGFR | − 5.35 | − 4.90 | − 5.43 | −5.21 | −4.38 | 3.13 |
Fig. 6Molecular docking patterns of main ingredients and key targets of YQCP
Fig. 7The overall mechanism of the YQCP on RA therapy